Inhibition of IFN-α/β signaling by two discrete peptides within measles virus V protein that specifically bind STAT1 and STAT2  by Caignard, Grégory et al.
Virology 383 (2009) 112–120
Contents lists available at ScienceDirect
Virology
j ourna l homepage: www.e lsev ie r.com/ locate /yv i roInhibition of IFN-α/β signaling by two discrete peptides within measles virus V
protein that speciﬁcally bind STAT1 and STAT2
Grégory Caignard a, Mehdi Bouraï a, Yves Jacob b, The Infection-MAPping project I-MAP a,c,
Frédéric Tangy a,⁎, Pierre-Olivier Vidalain a
a Laboratoire de Génomique Virale et Vaccination, CNRS URA 3015, Institut Pasteur, 28 rue du Dr. Roux, 75724 Paris Cedex 15, France
b Unité postulante de Génétique, Papillomavirus et Cancer Humain, 25 rue du Dr. Roux, 75724 Paris Cedex 15, France
c INSERM U851-Immunobiologie fondamentale et clinique, IFR128-BioSciences, 21 Avenue Tony Garnier, Lyon-Gerland, 69365 Lyon Cedex 07, France⁎ Corresponding author. Fax: +33 1 40 61 31 67.
E-mail address: ftangy@pasteur.fr (F. Tangy).
0042-6822/$ – see front matter © 2008 Elsevier Inc. Al
doi:10.1016/j.virol.2008.10.014a b s t r a c ta r t i c l e i n f oArticle history: The V protein of measles v
Received 7 July 2008
Returned to author for revision
26 August 2008
Accepted 9 October 2008







Peptideirus (MV-V) is a potent inhibitor of IFN-α/β signaling pathway. We previously
reported that when physically dissociated, the N-terminal and C-terminal regions of MV-V (PNT and VCT,
respectively) could independently impair signal transduction. The PNT region inhibited IFN-α/β signaling by
interacting with at least two components of this pathway: Jak1 and STAT1. Here we report a direct interaction
between the VCT of MV-V and STAT2, a third component of IFN-α/β transduction machinery. This interaction
with STAT2 is carried by the cysteine-constrained peptide of 49 amino acids localized in the VCT region, and is
essential to the inhibition of IFN-α/β signaling. In parallel, we alsomapped STAT1 binding site in the PNT region
and identiﬁed aminimal peptide of only 11 amino acids. IFN-α/β signalingwas impaired in human cells treated
with this MV-V peptide fused to a cell-penetrating sequence. Finally, we show that signaling downstream of
IFN-λ, a recently identiﬁed cytokine that also relies on STAT1, STAT2 and Jak1 to transduce, is blocked byMV-V.
Altogether, our results illustrate how a single viral protein has evolved to achieve a robust inhibition of the
antiviral response by interacting with several signaling molecules.
© 2008 Elsevier Inc. All rights reserved.IntroductionIn spite of the widespread use of an efﬁcient live attenuated vac-
cine, measles remains a major cause of infant mortality in the world
responsible for 345,000 deaths annually (Wolfson et al., 2007).
Measles virus (MV) infection induces a transient but profound immu-
nosuppression that accounts for the high frequency of opportunistic
infections associated with this disease. MV is a member of Paramyxo-
viridae family andMorbillivirus genus (Fields et al., 2001). Its genome is
a single-strand, negative-sense RNA that encodes for six structural
proteins.While hemagglutinin (H) and fusion (F) aremembrane glyco-
proteins associated with the envelope of MV particles, the nucleopro-
tein (N), the phosphoprotein (P) and the viral polymerase (L) are
components of the ribonucleocapsid complex. The matrix protein (M)
is located at the interface between glycoprotein tails and ribonucleo-
capsids, thereby contributing to the budding of viral particles.
In addition to phosphoprotein, the P gene ofMorbilliviruses encodes
two virulence factors, C and V (Devaux et al., 2008; Patterson et al.,
2000). An opened reading frame embedded in the ﬁrst half of the P
gene encodes the C protein (Bellini et al., 1985). The C protein of MV isl rights reserved.required for an optimal viral growth both in vitro and in vivo (Takeuchi
et al., 2005), but its main function remains unclear. The V protein of
measles virus (MV-V) is an essential virulence factor encoded by an
editing strategy (Cattaneo et al., 1989; Devaux et al., 2008). A non-
templated guanine nucleotide is inserted at a speciﬁc position of
mRNAs transcribed from the P gene (Fig. 1A). As a consequence, MV-V
is similar to the phosphoprotein P in its amino-terminal part (AA 1–
231; PNT region) but exhibits a speciﬁc cysteine-rich C-terminus that
folds in a zinc-ﬁnger domain (AA 232–299; VCT region). AlthoughMV-
V is probably multifunctional, its critical role in the inhibition of type I
interferons (IFN-α/β) signaling has been well documented (Palosaari
et al., 2003; Takeuchi et al., 2003; Yokota et al., 2003). IFN-α/β are
major antiviral cytokines that transduce through well-characterized
intermediates (Stark et al., 1998). Their binding to IFNAR1/IFNAR2c cell
surface receptor activates Tyk2 and Jak1 kinases to phosphorylate
STAT1 and STAT2 transcription factors. Activated STAT1 and STAT2,
altogether with IRF9, form the Interferon-Stimulated Gene Factor 3
(ISGF3) that binds IFN-stimulated response element (ISRE) promoter
sequences to stimulate the expression of antiviral genes, thus leading
viruses to evolve inhibitory mechanisms. MV-V interferes with this
pathway by interacting with components of the IFN-α/β signaling
pathway in amultiprotein complex (Palosaari et al., 2003; Yokota et al.,
2003). This interference mechanism protects the virus from the
antiviral activity of IFN-α/β in infected cells, while these cytokines
Fig. 1. The VCT region of MV-V interacts directly with STAT2. (A) Diagrams of MV-P and MV-V showing the position where RNA edition occurs. Deleterious mutations Y110H and
C272R that are characteristic of Ed-Tag infectious clone (Ohno et al., 2004), and W240A/W250A mutations investigated in this report are indicated with arrows. (B) HEK-293T cells
were transfected with expression vectors encoding GST alone or fused to MV-V or MV-P proteins, and tested for interaction with endogenous STAT2. Total cell lysates were prepared
48 h post-transfection (cell lysate; middle and lower panels), and co-puriﬁcation of endogenous STAT2 was assayed by pull-down using glutathione-sepharose beads (GST pull-
down; upper panel). GST-tagged MV-V and MV-P were detected by immunoblotting using anti-GST antibody, while endogenous STAT2 was detected with a speciﬁc monoclonal
antibody. (C) Similar experiment, but HEK-293T cells were co-transfected with expression vectors encoding GSTalone or fused to the PNTor VCT regions of MV-V, and 3xFLAG-tagged
STAT2. Tagged proteins were detected by immunoblotting using anti-GST or anti-3xFLAG antibodies. (D) Interaction of STAT2 with the VCT region of MV-V was analyzed in the yeast
two-hybrid system. Yeast cells expressing the PNT or VCT regions of MV-V fused to the Gal4 DNA binding domain (DB) were co-transformed with a plasmid encoding the Gal4
transactivation domain (AD) alone or fused to either STAT1 or STAT2. Yeast cells were plated on a selectivemedium lacking histidine and supplemented with 10mM 3-amino-triazole
(3-AT) to test the interaction-dependent transactivation of HIS3 reporter gene.
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key components of the immune system such as dendritic cells (Hahm
et al., 2005).
Recently, we identiﬁed STAT1 and Jak1 as direct interactors of the
PNT region of MV-V, and documented how these two interactions
inhibit STAT1 phosphorylation by Jak1 (Caignard et al., 2007). This
provides molecular basis on how the PNT region alone can affect IFN-
α/β signaling. However, inhibition by the PNT region is only partial, as
compared to that observed with full-length MV-V, suggesting that the
VCT region is also involved. Accordingly, a mutation in the PNT region
(Y110H) that impairs STAT1 binding must be combined with a second
mutation in the VCT region (C272R) to abrogate MV-V inhibitory
activity (Caignard et al., 2007; Devaux et al., 2007; Fontana et al., 2008;
Ohno et al., 2004) (Fig. 1A). We also demonstrated that the VCT region
alone can impair IFN-α/β signaling (Caignard et al., 2007). Altogether,
these observations suggested that the VCT region has a speciﬁc partner
in the IFN-α/β receptor complex. In agreement with this hypothesis,
we now demonstrate that the VCT region of MV-V fromwild-type IC-B
strain interacts directly with cellular STAT2. In addition, we preciselymapped the STAT1 and STAT2 binding sites embedded in the PNT and
VCT regions of MV-V, respectively. When preparing this manuscript,
Ramachandran et al. published a similar study on the MV-V protein of
Edmonston ATCC strain (Ramachandran et al., 2008). Their data are
compared to our results in the Discussion section of this manuscript.
Results
The VCT region of MV-V protein binds directly to STAT2
We previously reported that both the PNT and VCT regions contri-
bute to the inhibition of IFN-α/β signaling by MV-V. This was demon-
strated using a luciferase reporter gene controlled by an artiﬁcial
promoter sequence containing multiple ISRE copies. We now report
similar results with reporter constructs driven by promoter sequences
from IFN-stimulated genes ISG54 and ISG56 (Table 1). STAT1 and Jak1
interactions account for the inhibitory activity of the PNT region
(Caignard et al., 2007), but how IFN-α/β signaling is impaired by the
VCT region remains unknown. Because co-afﬁnity puriﬁcation
Table 1
MV-V, MV-PNT and MV-VCT regions impair type I IFN signaling
IFN-β with None MV-V MV-PNT MV-VCT
pISRE-Luc 100 9.3±0.8 55.5±3.9 30.6±3.3
pISG54-Luc 100 1.7±0.0 3.5±0.3 14.4±0.8
pISG56-Luc 100 10.5±0.5 21.0±1.2 27.5±4.4
Transfected cells were stimulated with 1000 IU/ml of IFN-β and expression of luciferase
reporter constructs controlled by ISRE repeats (pISRE-Luc) or promoter sequences of
ISG54 or ISG56 (pISG54-Luc and pISG56-Luc, respectively) was quantiﬁed. Results were
normalized so that reporter activity in cells transfected with a control vector equals 100.
Experiments were performed in triplicates and data represent means±SD.
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tion of a protein complex containing multiple cellular partners
including STAT2 (Palosaari et al., 2003), we tested the possibility that
the VCT region targets this essential component of IFN-α/β pathway.
We ﬁrst compared the ability of MV-V and MV-P viral proteins to
interact with endogenous cellular STAT2 (Fig.1B). HEK-293Tcells were
transfected with expression vectors encoding GST alone or fused to
MV-V or MV-P proteins. GST-tagged viral proteins were puriﬁed with
glutathione-sepharose beads and tested for interaction with endo-
genous STAT2. Cellular STAT2 co-puriﬁed with MV-V but not MV-P or
GST alone (Fig. 1B). This conﬁrms previous reports showing MV-V and
STAT2 in the same protein complex (Palosaari et al., 2003), but also
shows the critical role of the VCT region in this interaction. To demons-
trate STAT2 binding to the VCT region alone, cells were transfected
with either GST fused to PNTor VCT regions in the presence of 3xFLAG-
tagged STAT2. The VCT region interactedwith STAT2 identically to full-
lengthMV-V, while the PNT region did not (Fig. 1C). To further validate
this direct interaction in a heterologous system that does not express
other IFN-α/β signaling components, VCT binding to STAT2was tested
in yeast (Fig. 1D). The VCT region fused to Gal4 DNA binding domain
speciﬁcally interacted with STAT2 fused to Gal4 activation domain inFig. 2. Yeast two-hybrid mapping of MV-V binding region to STAT2. (A) Systemic deletion-b
matrix combination of speciﬁc primers, and introduced into Gal4-DB vector by gap-repair in
medium lacking histidine and supplemented with 10 mM of 3-amino-triazole (3-AT) to test t
axes indicate the ﬁrst and the last amino acid residues of each fragment tested, respectively
identiﬁcation of a 49 amino acid peptide encompassing position 232 to 280 of MV-V as thethe yeast two-hybrid system (Y2H; Fig. 1D), while the PNT region only
interacted with STAT1 as previously reported (Caignard et al., 2007).
Altogether, our data demonstrate the direct binding of STAT2 to the
VCT region of MV-V, independently of the PNT region and the
interaction with STAT1.
Mapping of MV-V binding site to STAT2
In order to characterize STAT2 binding interface on MV-V, we ge-
nerated a full matrix of VCT overlapping fragments by PCR and tested
their ability to interact with STAT2 in the Y2H system (Fig. 2). Both
forwardand reverse primersweredesignedevery36nucleotides along
VCT sequence and fused to appropriate sequences to allow gap-repair
recombination with linearized Gal4-DB Y2H vector. All possible com-
binations of forward and reverse primers were used to amplify VCT
fragments (Fig. 2A). Finally, corresponding PCR products were transf-
ormed in a yeast strain expressing AD-fused STAT2, and growth on
selectivemediumwas used todetect potential interactions. A 58 amino
acid-long peptide encompassing position 231 to 288 of MV-V was
sufﬁcient to bind STAT2 (Fig. 2B). In an iterative process, we then
generated a second and a third set of VCT fragments corresponding to
one-by-one amino acid deletions (Figs. 2C and D), allowing to further
reduce the STAT2 bindingmotif to aminimal peptide of 49 amino acids
(MV-V232–280). Because the VCT region alone was previously reported
to impair IFN-α/β signaling when expressed in human cells, we tested
the minimal MV-V232–280 peptide for this activity. HEK293T cells were
transfected with an ISRE-luciferase reporter gene in the presence of
VCT,MV-V orMV-V232–280 and stimulated 24 h laterwith IFN-β (Fig. 3).
IFN-α/β signaling was strongly impaired by MV-V, whereas the
inhibition by the VCT region alone was less pronounced as reported
before (Caignard et al., 2007). Inhibition of IFN-α/β signaling by MV-
V232–280was similar to the VCT region. As shown in Fig. 4A, this peptide
extends from the beginning of the VCT region to the end of theased mapping procedure. Fragments of the VCT region were generated by PCR using a
yeast cells expressing STAT2 fused to Gal4-AD. (B–D) Yeast cells were grown on selective
he interaction-dependent transactivation of HIS3 reporter gene. Vertical and horizontal
. (B–D) correspond to three iterations of this process. (D) The third iteration led to the
minimal STAT2 binding peptide.
Fig. 3. Inhibition of IFN-α/β signaling by MV-V232–280. HEK-293T cells were transfected
with pISRE-Luc, pRL-CMV, and expression plasmids encoding either MV-V, the VCT
region alone or MV-V232–280. 24 h after transfection, 1000 IU/ml of recombinant IFN-β
were added. After 24 h, relative luciferase activity was determined. Experiments were
performed in duplicates, and data represent means±SD.
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idae expressing a V protein (Horvath, 2004). In contrast, the last 19
amino acids of MV-V (AA 281–299) were not critically required for the
interaction with STAT2.
Using as a template the crystal structure of the V protein of Simian
Virus 5 (SV5), another Paramyxoviridae (Li et al., 2006), we determined
a 3D model of the C-terminal region of MV-V (AA 226–283) using
SwissModel (Arnold et al., 2006; Guex and Peitsch, 1997) (Fig. 4B). On
this structure prediction, the MV-V232–280 peptide overlaps with the
zinc-ﬁnger fold formed by the cysteine residues of the VCT region (Fig.
4B, left panel). The shorter peptides generated in Fig. 2Dwere probably
unable to properly fold, thereby losing their capacity to bind STAT2. In
addition to the well-characterized cysteine cluster, MV-V232–280
contains two tryptophan residues separated by 9 amino acids just
upstream of the cysteine cluster, respectively at positions 240 and 250
(Fig. 4A). This is reminiscent of a W-(X)3-W-(X)9-W tryptophan motif
previously identiﬁed at the same position in the V protein of Rubula-
viruses (Nishio et al., 2002, 2005). These viruses encode a V protein that
interacts with STATs to induce their degradation, and the W-(X)3-W-
(X)9-W tryptophanmotif is required in this process (Nishio et al., 2002,
2005). Interestingly, tryptophan 240 from MV-V corresponds to
tryptophan 179 from the V protein of SV5, a residue that is a part of
bowl-shapeddepression at the surface of the SV5-V protein involved in
the interactionwith STAT2 (Li et al., 2006). Tryptophan240 and 250 are
exposed at the surface of the VCT structure (Fig. 4B, right panel). We
thus tested the consequences of substituting tryptophan by alanine at
positions 240 and 250. As shown in Fig. 4C, W240A or W250A muta-
tions strongly impairedVCTbinding to STAT2. Thesemutantswere also
tested for their ability to affect IFN-α/β signaling using an ISRE-
luciferase reporter assay. W240A and W250A mutants were severely
affected for their capacity to block IFN-α/β signaling when compared
to the wild-type VCT region (Fig. 4D). Thus, tryptophans 240 and 250
are required for the VCT region of MV-V to interact with STAT2 and to
block IFN-α/β pathway. As expected, full-length MV-V carrying the
same W250A mutation was only partially impaired for its ability to
block IFN-α/β signaling (Fig. 4D). Indeed, interactions with STAT1 and
Jak1 kinase domain (Jak1-TK) that bind to the PNT region ofMV-Vwere
not affected by this mutation and the loss of interaction with STAT2
(Fig. 4E).
Mapping of MV-V binding site to STAT1
The PNT region of MV-V interacts with another STAT protein, i.e.
STAT1, but does not exhibit a zinc-ﬁnger domain like the VCT region.To preciselymap STAT1 binding site, we applied the strategy described
in Fig. 2A to the PNT region. A 31 amino acid peptide encompassing
position 101 to 131 of the PNT regionwas sufﬁcient to bind STAT1 (Fig.
5A). STAT1 bindingmotif was further characterized using a second and
third set of PNT fragments (Figs. 5B and C) to ﬁnally map an 11 amino
acid peptide that could not be reduced anymore (MV-V110–120). The
sequence of this peptide is 110YHVYDHSGEAV120, and corresponds to
the minimal portion of MV-V required to mediate an interaction with
STAT1 in the yeast two-hybrid system. This peptide is highly
conserved among all Morbilliviruses (Devaux et al., 2007). Its ﬁrst
residue corresponds to tyrosine 110 that is essential for the interaction
between MV-V and STAT1 (Caignard et al. 2007, Fontana et al. 2008).
Whenmutated to histidine in the MV-V110–120 peptide, the interaction
with STAT1 was lost as expected (Fig. 5C).
To demonstrate the critical role of this peptide in the interaction
with STAT1 in human cells, different fragments of MV-V containing or
not this peptidewere expressed in HEK-293Tcells (Fig. 6A). Co-afﬁnity
puriﬁcation experiments showed that a fragment of PNT encompass-
ing amino acid 110 to 231 (Fig. 6B, fragment 1) interacted with STAT1,
whereas the same fragment depleted of the MV-V110–120 peptide did
not (Fig. 6B, fragment 2). Identical results were obtained using larger
fragments containing the VCT region (Fig. 6B, fragments 5 and 6),
again demonstrating the critical role of the MV-V110–120 peptide in the
interaction with STAT1. Surprisingly, fragment 3 encompassing amino
acids 1 to 120 was inefﬁcient to bind STAT1. This suggested that amino
acids 121 to 231 (Fig. 6B, fragments 1 and 5) increase the afﬁnity of
the MV-V110–120 peptide for STAT1, whereas amino acids 1 to 109 (Fig.
6B, fragment 3) are unable to perform this peculiar function. In
agreement with this observation, we were also unable to co-purify
STAT1 using the MV-V110–120 peptide alone (data not shown). When
the MV-V110–120 peptide is taken out of its context, its afﬁnity for
STAT1 is probably too weak and the interaction cannot be detected by
co-puriﬁcation experiments. However, this interaction between the
MV-V110–120 peptide alone and STAT1 is detectable in a more sensitive
assay like the two-hybrid system (Fig. 5C) (Yang, Wu, and Fields,
1995).
We tested the ability of the MV-V110–120 peptide to block IFN-α/β
signaling in human cells. First, HEK-293T cells were co-transfected
with a plasmid expressingMV-V110–120 and an ISRE-luciferase reported
construct. Like the PNT region alone (Caignard et al., 2007), inhibition
of the luciferase activity by MV-V110–120 was signiﬁcant, although
relatively modest when compared to full-length MV-V (Fig. 7A).
This demonstrated that in spite of a weak afﬁnity for its cellular target,
MV-V110–120 could signiﬁcantly alter IFN-α/β signaling. Then, we
synthesized the MV-V110–120 peptide in fusionwith 8K or Tat47–57 cell-
penetrating sequences (Tilstra et al., 2007). 8K or Tat47–57 cell-
penetrating sequences belong to a family of short cationic peptides
that are able to carry larger molecules across cellular membranes and
were used to transduce MV-V110–120. HEK-293T cells were transfected
with the ISRE-luciferase construct and treated with synthetic peptides
6 h before the IFN-β stimulation. Treatment of the cells with Tat47–57-
MV-V110–120 or 8K-MV-V110–120 inhibited expression of the ISRE-
luciferase gene when compared to cells treated with the MV-V110–120
peptide without a cell-penetrating sequence (Fig. 7B). Tat47–57 alone
was inactive, demonstrating that it was not responsible for the
inhibition observed. Moreover, a mutant peptide carrying the
Y110H mutation (Tat47–57-MV-VY110H–120) and therefore impaired
for its ability to interact with STAT1 was also inactive. Lastly, we
analyzed the kinetics of 8K-MV-V110–120 peptide activity. Cells
transfected with the ISRE-luciferase construct were treated with
2 μg/ml of 8K-MV-V110–120 at different time-points before or after
IFN-β stimulation (Fig. 7C). The inhibition was maximal when
treating the cells 6 h before stimulation. These results establish that
an 11-amino acid peptide derived from MV-V protein is sufﬁcient to
alter the IFN-α/β signaling pathway when present in the cytoplasm
of target cells.
Fig. 4. Two tryptophan residues in the VCT region of MV-V are conserved among Morbilliviruses and Rubulaviruses and required for the interaction with STAT2. (A) Identiﬁcation of
tryptophan residues conserved upstream of the cysteine cluster in the VCT region of MV-V. Sequences from human parainﬂuenza virus 2 (hPIV2, NP_598402.1), Mumps virus
(NP_054709.1), Simian Virus 5 (SV5, YP_138513.1), andMeasles virus (NC_001498.1) were alignedwith CLCWorkbench 4.0.1. Amino acid conservation rate is indicated by a histogram
below the alignment. Conserved tryptophan and cysteine residues are highlighted by shadow boxes and stars, respectively. STAT2 binding peptideMV-V232–280 is delimited by a black
box. (B) A 3Dmodel of MV C-terminal region (AA 226–283) was determined by SwissModel (Arnold et al., 2006) using the crystallographic structure of V from SV5 as a template (Li et
al., 2006). This structure is displayed as a ribbon model (left panel) or a molecular surface (right panel) using SPDB-Viewer (Guex and Peitsch, 1997). Cysteine residues that compose
the zinc-ﬁnger are shown in turquoise, W240 and W250 in purple, and STAT2 binding peptide in yellow. F246 and D248, identiﬁed by others as essential for the interaction with
STAT2, are shown in red (Ramachandran et al., 2008). (C) W240A and W250A mutants were deeply affected for the interaction with STAT2. HEK-293T cells were co-transfected with
expression vectors encoding 3xFLAG-tagged STAT2 and GST alone or GST fused to wild-type or mutant VCT region. Tagged proteins were detected by immunoblotting using anti-GST
or anti-3xFLAG antibodies. (D) W240A and W250A mutants were impaired for their ability to block IFN-α/β signaling when compared to the wild-type VCT region. HEK-293T cells
were transfected with pISRE-Luc, pRL-CMV, and expression plasmids encoding wild-type or mutant MV-V or VCT. 24 h after transfection, 1000 IU/ml of recombinant IFN-β were
added. After 24 h, relative luciferase activity was determined. Experiments were performed in triplicates, and data represent means±SD. (E) MV-V mutant W250A interacts with
STAT1 and Jak1 but not STAT2. HEK-293T cells were co-transfected with 3xFLAG-tagged STAT1, STAT2 or Jak1 kinase domain (Jak1-TK) and GST fused to wild-type MV-V or mutant
with the W250A mutation. After puriﬁcation of GST-fusion proteins, tagged proteins were detected by immunoblotting using anti-GST or anti-3xFLAG antibodies.
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Fig. 5. An 11 amino acids peptide of MV-V is sufﬁcient to bind STAT1. Fragments of PNT
regionwere generated and tested for their ability to interact with STAT1 as described in
Fig. 2A. (A) The ﬁrst iteration identiﬁed a STAT1 binding peptide of 31 amino acids. After
two (B) and three additional rounds (C), this peptide was ﬁnally reduced to 11 amino
acids as aminimal STAT1 bindingmotif. ⁎110 on the vertical axis refers to PNT fragments
containing the deleterious Y110H mutation reported to disrupt the interaction with
STAT1.
Fig. 6.MV-V requires the MV-V110–120 peptide to interact with STAT1 in human cells. (A)
Different fragments of MV-V were designed with or without STAT1 binding peptide. (B)
HEK-293T cells were transfected to co-express GST fused to MV-V fragments and
3xFLAG-tagged STAT1. Tagged proteins were detected by immunoblotting using anti-
GST or anti-3xFLAG antibodies.
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Altogether, our data demonstrate that MV-V not only interacts
directly with STAT1 and Jak1 by its PNT region, but also with STAT2 by
its VCT region. Interestingly, these three signalingmolecules are shared
components of IFN-α/β and IFN-λ pathways. Recently identiﬁed type
III interferons, that include IFN-λ1, IFN-λ2 and IFN-λ3 (also known as
IL-29, IL-28A, and IL-28B), have been shown to bind a speciﬁc
membrane receptor called IFNLR1/IL10R2 which is distinct from IFN-
α/β receptor (IFNAR1/IFNAR2c). But IFN-λ requires Jak1, STAT1 and
STAT2 to activate interferon-stimulated genes (Uze and Monneron,
2007). Upon IFN-λ stimulation, Tyk2 and Jak1 respectively associated
with IL10R2 and IFNLR1 receptor subunits induce ISGF3 formation by
phosphorylating STAT1 and STAT2. We thus tested the ability of MV-Vto block signaling downstreamof IFN-λ. Cells were transfectedwith an
ISRE-luciferase reporter construct in the presence or not of MV-V, then
stimulated with IFN-λ1. Signaling was deeply impaired by MV-V (Fig.
8). PNTand VCT regionswere also tested for their ability to block IFN-λ
signaling. In agreement with results obtained with IFN-α/β, both PNT
andVCT regions impaired IFN-λ signaling although less efﬁciently than
full-length MV-V protein. This demonstrates that signaling inhibition
by MV-V is not restricted to IFN-α/β pathway as transduction down-
stream of IFN-λ receptor is efﬁciently blocked by this viral protein.
Discussion
MV-V is a potent inhibitor of IFN-α/β transduction pathway and
critically contributes to the hijacking of cellular antiviral functions by
MV. In this report,wehave identiﬁed STAT2 as a direct target of theVCT
region of MV-V (wild-type IC-B strain). Recently, the same observation
has been reported by Ramachandran et al. for the Edmonston ATCC
strain of MV (Ramachandran et al., 2008). Altogether with STAT1 and
Jak1, STAT2 is the third component of the IFN-α/β signaling pathway
reported to bindMV-V directly. These three interactions allowMV-V to
form amultiprotein complex with IFN-α/β signaling components, and
block signaling downstream of IFN-α/β receptor (Palosaari et al.,
2003). We also showed that MV-V interferes with IFN-λ signaling,
demonstrating that MV-V mediated inhibition is not restricted to IFN-
α/β pathway and IFNAR1/IFNAR2c receptor complex. This supports a
critical role of MV-V interactions with Jak1, STAT1 and STAT2 in the
inhibition of both IFN-α/β and IFN-λ pathways.
MV-V interactionwith STAT2 is carried by the zinc-ﬁnger domain of
the VCT region (AA 232-280), but does not rely on the last 19 residues
of MV-V (Fig. 4A) in agreement with (Ramachandran et al. 2008). This
minimal STAT2 binding peptide contains the cysteine cluster that is a
Fig. 7. Inhibition of IFN-α/β signaling by STAT1 binding peptide MV-V110–120. (A) HEK-
293T cells were transfected with pISRE-Luc, pRL-CMV, and expression plasmids
encoding MV-V or MV-V110–120. 24 h after transfection, 1000 IU/ml of recombinant
IFN-β were added. After 24 h, relative luciferase activity was determined. Experiments
were performed in triplicates, and data represent means±SD. (B) HEK-293T cells were
transfected with pISRE-Luc and pRL-CMV. 24 h later, cells were treated with 5 μg/ml of
synthetic peptides corresponding to MV-V110–120, the cell-penetrating sequence of Tat
alone (Tat47–57), MV-V110–120 fused to Tat47–57 (Tat47–57-MV-V110–120), the same peptide
carrying the Y110H mutation (Tat47–57-MV-VY110H–120) or MV-V110–120 fused to the cell-
penetrating sequence KKKKKKKK (8K-MV-V110–120). After 6 h, cellswere stimulatedwith
1000 IU/ml of recombinant IFN-β. After 24 h, relative luciferase activitywas determined.
Experiments were performed in triplicates, and data represent means±SD. P-values
were calculated by the Student's t-test (C) The same experiment was performed with
2 μg/ml of 8K-MV-V110–120 synthetic peptide. Cells were treated at 24 h, 6 h, 4 h, 2 h
before the stimulation with IFN-β or 18 h later.
Fig. 8. Inhibition of IFN-λ signaling by MV-V. HEK-293T cells were transfected with
pISRE-Luc, pRL-CMV, and expression plasmids encoding MV-V protein, PNT region, or
VCT region. 24 h after transfection, 1000 IU/ml of recombinant IFN-λ1were added. After
24 h, relative luciferase activity was determined. Experiments were performed in
triplicates, and data represent means±SD.
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addition, we showed that tryptophans 240 and 250 are critical for
the interaction with STAT2. Localized upstream of the cysteine cluster
on the primary sequence, the position of these tryptophan residues is
reminiscent of the W-(X)3-W-(X)9-Wmotif previously involved in the
binding of the V protein of Rubulaviruses to STATs (Nishio et al., 2002,
2005). This motif may represent a conserved STAT-binding site for
Morbilliviruses and Rubulaviruses. But in contrast to Morbilliviruses,
STAT2 interaction with V from Rubulaviruses seems to require the PNT
and VCT regions together (Li et al., 2006; Ramachandran et al., 2008;
Ulane et al., 2005). According to the structure prediction currentlyavailable, tryptophan 240 and 250 are exposed at the surface of the
protein fold deﬁned by the VCT region. Although we cannot speculate
on the exposition of these residues in the context of full-length MV-V,
they are probably part of the binding interface to STAT2. Two other
mutations (F246R and D248F) were also shown to disrupt the inter-
actionwith STAT2 (Ramachandran et al., 2008). Altogether withW240
andW250, these four residues exposed at the surface of the VCT region
roughly deﬁne the STAT2 binding site (Fig. 4B, right panel). In addition
to STAT2, the VCT region of MV-V was previously reported to interact
with MDA5, thereby inhibiting the induction of IFN-β when stimulat-
ing cells with double-stranded RNA (Childs et al., 2007). An interaction
with p53 family member p73 was also reported, allowing MV-V to
inhibit apoptosis (Cruz et al., 2006). It will be interesting to precisely
map the binding sites ofMDA5 and p73 at the surface of the VCT region
ofMV-V, and understand how this relatively small domain has evolved
multiple binding interfaces contributing to the ﬁtness of measles virus
in vivo.
Whereas STAT2 binds to the VCT region, the PNT region mediates
MV-V interaction with STAT1 and Jak1. We previously reported that
STAT1 and Jak1 binding sites are distinct (Caignard et al., 2007). Indeed,
STAT1 does not competewith Jak1 for the interactionwithMV-Vwhen
co-expressed. Moreover, MV-V carrying the Y110H mutation fails to
bind STAT1 but still interacts with Jak1. In this report, we identiﬁed an
11 amino acid peptide, MV-V110–120, as a minimal STAT1 binding se-
quence. This is in agreementwith a recent report showing that AA110–
130 are required for MV-V interaction with STAT1 (Ramachandran et
al., 2008). The MV-V110–120 peptide alone was functional: human cells
transfected with an expression vector encoding for MV-V110–120 or
treated with a synthetic peptide fused to a cell-penetrating sequence
were signiﬁcantly impaired for IFN-α/β signaling. Moreover, a mutant
peptide carrying the Y110H mutation and therefore impaired for its
ability to interact with STAT1 was unable to do so. Because the N-
terminal region of MV-V is intrinsically disordered, we expected this
kind of linear bindingmotif (Karlin et al., 2002). However, MV-V110–120
afﬁnity for STAT1 was relatively low, and the interaction was only
detectable in a sensitive assay like the yeast two-hybrid system (Yang
et al.,1995). Interestingly, this interactionwas strengthenedwhenMV-
V110–120 was fused to amino acids 121–231 of MV-V, and became
detectable byco-afﬁnity puriﬁcation. These residues could stabilize the
interaction of MV-V110–120 with STAT1 by contributing to the interac-
tion-induced folding of the PNT region when contacting STAT1.
Another hypothesis is that amino acids 121–231 of MV-V bind Jak1.
Because Jak1 and STAT1 interact with each other (Fujitani et al., 1997;
Gupta et al.,1996), this could indirectly stabilizeMV-V110–120 binding to
STAT1. Similarly to the STAT2 binding domain described above, the
peptidic motif interacting with STAT1 is highly conserved among all
119G. Caignard et al. / Virology 383 (2009) 112–120Morbilliviruses, attesting of the positive selection that applies on this
short sequence.
In our STAT-binding assays, the PNT and VCT regions of MV-V
behaved as autonomous modules. When dissociated, they were still
able to interact with STAT1 and STAT2, respectively, and to alter IFN-α/
β and IFN-λ signaling. In agreement with this observation, MV-V
mutated in the VCT region to disrupt the interaction with STAT2
remained fully competent to recruit cellular STAT1 (Fig. 4E) (Rama-
chandran et al., 2008). Surprisingly, Ramachandran et al. reported that
the PNT region expressed alone is signiﬁcantly impaired for its ability
to co-purifywith endogenous STAT1. This could be explained if the VCT
region, in addition to the interactionwith STAT2, also contributes to the
proper folding of the PNT region, and thereby stabilizes the PNT
interaction with STAT1 when this cellular factor is expressed at low
levels. Altogether, the identiﬁcation of two STAT-binding sites in MV-V
provides molecular basis to a previous report showing that two
deleterious mutations, one in the PNT region (Y110H) and the other in
the VCT region (C272R), are required to totally abrogate the inhibitory
capacity ofMV-Vwhen tested against IFN-α/β (Ohno et al., 2004). Both
STAT1 and STAT2 binding interfaces must be disrupted to abrogate the
inhibitory activity ofMV-V. It also explainswhy, in contrast to IFN-α/β,
a single mutation in the PNT region at position 110 is sufﬁcient to
prevent MV-V from inhibiting the IFN-γ pathway (Fontana et al.,
2008). Indeed, IFN-γ only relies on STAT1 homodimers to transduce,
and the VCT interaction with STAT2 is needless in this context.
Finally, it was recently shown by others that in the absence of
STAT2, MV-V interactionwith STAT1 is greatly impaired, whereas MV-
V mutants that fail to interact with STAT2 still efﬁciently bind STAT1
(Ramachandran et al., 2008). Because STAT1 and STAT2 are bound
together in resting cells, this interaction is probably required for the
proper folding of STAT1 and its interaction with the PNT region. Thus,
STAT1–STAT2 interaction also contributes to the overall stability of the
STAT1/STAT2/MV-V heterotrimer, freezing these signaling molecules
in a complex where they are trapped. In the future, the precise
structure of MV-V when interacting with STAT1, Jak1 and STAT2 will
need to be determined. The identiﬁcation of MV-V binding sites for
STAT1 and STAT2 will be instrumental to reach this goal.
Materials and methods
ORF cloning, plasmid constructs and synthetic peptides
All viral constructs were ampliﬁed by standard PCR (ExTaq; Takara)
method, and cloned into pDONR207 (Invitrogen) using an in vitro
recombination-based cloning system (Gateway system; Invitrogen) as
previously described (Caignard et al., 2007). ORFs encoding full-length
MV-V, the PNT domain (AA 1–231) and the VCT domain (AA 232–299)
were ampliﬁed from an infectious clone of IC-B strain kindly provided
by Dr K. Takeuchi (University of Tsukuba, Japan; Genbank ID:
NC001498)(Takeda et al., 2000). STAT2 coding sequencewas ampliﬁed
from a human spleen cDNA library (Invitrogen) before cloning into
pDONR207 (Invitrogen). Plasmids containing STAT1 or Jak1 kinase
domain (Jak1-TK) were previously described (Caignard et al., 2007).
Tryptophan to alanine mutations at positions 240 and 250 of the VCT
region of MV-V were introduced by site-directed mutagenesis
(QuikChange® Lightning kit, Stratagene), then sequence veriﬁed.
Subsequently, viral or cellular ORFs were transferred by in vitro re-
combination from pDONR207 in different Gateway-compatible desti-
nation vectors (see below) following manufacturer's recommendation
(LR cloning reaction, Invitrogen). Synthetic peptides corresponding to
the MV-V110–120 sequence fused either to 8 lysine residues (8K-MV-
V110–120: KKKKKKKKGGYHVYDHSGEAV) or to the Tat47–57 cell-pene-
trating sequence (Tat47–57-MV-V110–120: YGRKKRRQRRRGGYHVYDHS-
GEAV) were synthesized by Genecust (France). The cell-penetrating
domain of Tat fromHuman Immunodeﬁciency Virus (Tat47–57) was the
ﬁrst transduction peptide identiﬁed, whereas 8K is an optimalsequence selected by Mai et al. to transduce epithelial cell lines in
culture. Both peptides labeled with Alexa Fluor 488 were able to
transduce more than 99,7% of treated cells lines (Mai et al., 2002).
Co-afﬁnity puriﬁcation experiments
To perform co-afﬁnity puriﬁcation experiments, cloned ORFs were
transferred from pDONR207 to pDEST27 expression vector (Invitrogen)
to achieve GST fusion, and to pCI-neo-3xFLAG vector (Mendoza et al.,
2006) for 3xFLAG-fusion. Tagged proteins were expressed in human
HEK-293T cells maintained in Dulbecco's modiﬁed Eagle's medium
(DMEM; Gibco-Invitrogen) containing 10% fetal bovine serum, peni-
cillin, and streptomycin at 37 °C and 5% CO2. Cell transfections were
achieved using Lipofectamine 2000 (Invitrogen). Brieﬂy, 5×105 HEK-
293Tcells were dispensed in eachwell of a 6-well plate, and transfected
24 h later with 600 ng of each plasmid DNA per well. Two days after
transfection, HEK-293T cells were washed in phosphate-buffered saline
(PBS), then resuspended in lysis buffer (0.5% Nonidet P-40, 20mMTris–
HCl at pH=8, 120 mMNaCl and 1 mM EDTA) supplemented with Com-
plete Protease Inhibitor Cocktail (Roche). Cell lysates were incubated on
ice for 20 min, then clariﬁed by centrifugation at 14,000 ×g for 10 min.
For pull-down analysis, 400 μg of protein extracts were incubated for
1 h at 4 °C with 25 μl of glutathione-sepharose beads (Amersham
Biosciences) to purify GST-tagged proteins. Beads were then washed 3
times in ice-cold lysis buffer and proteins were recovered by boiling in
denaturing loading buffer (Invitrogen). Puriﬁed complexes and protein
extracts were resolved by SDS-polyacrylamide gel electrophoresis (SDS-
PAGE) on 4–12% NuPAGE Bis–Tris gels with MOPS running buffer
(Invitrogen), and transferred to a nitrocellulose membrane. 3xFLAG-
and GST-tagged proteinswere detected using standard immunoblotting
techniques. Membranes were blotted with a mouse monoclonal HRP-
conjugated anti-3xFLAG antibody (M2; Sigma-Aldrich) or a rabbit
polyclonal anti-GST antibody (Sigma-Aldrich). Endogenous STAT2 was
revealed using clone-22 (mouse monoclonal antibody; BD Biosciences).
Secondary anti-mouse and anti-rabbit HRP-conjugated antibodies were
from GE-Healthcare and Amersham, respectively.
Yeast two-hybrid procedure
Yeast culture mediums were prepared as previously described
(Walhout and Vidal, 2001). STAT1 and STAT2 were transferred by in
vitro recombination from pDONR207 in a Gateway-compatible pPC86
yeast expression vector (Invitrogen) to be fused with the activation
domain of Gal4 (AD-Gal4). These constructs were transformed in
AH109 yeast strains (Clontech) expressing either the PNTor VCT region
of MV-V fused to the DNA binding domain of Gal4 (Gal4-DB; pDEST32
vector; Invitrogen). Yeast cells were plated on a selective medium
lacking histidine and supplemented with 10 mM 3-amino-triazole (3-
AT; Sigma-Aldrich) to test the interaction-dependent transactivation of
HIS3 reporter gene.
To perform the reﬁned mapping of PNT or VCT binding sites to
STAT1 or STAT2,we used the gap-repair procedure (Walhout andVidal,
2001). First, both forward and reverse PCR primers were designed
every 75 nucleotides along the PNT sequence, or every 36 nucleotides
along the VCT sequence. These 20 to 25 bp long primers were fused to
speciﬁc tails allowing recombination in the Gal4-DB Y2H vector.




Matrix combinations of forward and reverse primers were used to
amplify PNT and VCT fragments by PCR. AH109 yeast cells expressing
AD-fused STAT1 or AD-fused STAT2 were co-transformed with 5 μL of
each PCR product in the presence 50 ng of linearized pDEST32 vector to
achieve recombinatorial cloning by gap-repair. PNT or VCT fragments
fused to Gal4-DB were then tested for interaction with AD-STAT1 or
120 G. Caignard et al. / Virology 383 (2009) 112–120AD-STAT2 by plating yeast cells on selective medium lacking histidine
(−His medium) and supplemented with 10 mM of 3-AT.
Luciferase reporter gene assay
Luciferase reporter plasmid pISRE-Luc was from Stratagene. We
thank Dr. Sandra Pellegrini (Institut Pasteur) for providing pISG54-Luc
made by David E. Levy (Bluyssen et al., 1994). We thank Eliane Meurs
(Institut Pasteur) for providing pISG56-Luc made by John Hiscott
(Grandvaux et al., 2002). HEK-293T cells were plated in 24-well plates
(2×105 per well). One day later, cells were transfected with pISRE-Luc,
pISG54-Luc or pISG56-Luc reporter plasmid (0.3 μg/well), pRL-CMV
reference plasmid that harbored a CMV promoter just upstream of the
Renilla luciferase gene (0.03 μg/well; Promega), and speciﬁed ORFs
cloned inpIRES2-DsRed2 vector (Clontech; 0.3 μg/well unless speciﬁed
otherwise). Transfection efﬁciencywas assessed under themicroscope
using dsRed protein ﬂuorescence. 24 h after transfection, cells were
stimulated with IFN-β (Biosource) or IFN-λ (R&D Systems) at 1000 IU/
ml. After 24 h, cells were lysed, and both ﬁreﬂy and Renilla luciferase
activities in the lysate were determined using the Dual-luciferase
Reporter Assay System (Promega). Reporter activity was calculated as
the ratio of ﬁreﬂy luciferase activity to reference Renilla luciferase ac-
tivity, and normalized so that positive control activity equals 100.
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